Ipsen shares fall after failed trial on experimental FOP drug

Ipsen SA

19/12/2025 08:39

** Shares in Ipsen IPN.PA fall about 2% after the French biopharmaceutical company said a pivotal trial for treatment of fibrodysplasia ossificans progressiva (FOP) failed to meet its primary endpoint

** Ipsen says Phase II FALKON trial evaluating investigational drug fidrisertib in adults and children with FOP, a rare genetic disorder causing abnormal bone growth in muscles, tendons and soft tissues, did not meet the endpoint of reducing new growths vs placebo

** J.P. Morgan analyst Richard Vosser calls the outcome a "minor negative", noting no value for fidrisertib was factored into Ipsen's forecasts

** He emphasises a limited downside risk, as analysts had minimal expectations for the experimental treatment

** The stock is among the worst performers on the SBF 120 index .SBF120 on Paris' most traded stocks

(Reporting by Clement Martinot)

((Clement.Martinot@thomsonreuters.com;))